Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma (Q57072034)

From Wikidata

Jump to navigation Jump to search

article

Language	Label	Description	Also known as
English	Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma	article

Statements

scholarly article

0 references

Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma (English)

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Peter A. Fasching

7

object named as

P A Fasching

0 references

11

object named as

H Brauch

0 references

author name string

T E Mürdter

1

0 references

W Schroth

2

0 references

L Bacchus-Gerybadze

3

0 references

S Winter

4

0 references

G Heinkele

5

0 references

W Simon

6

0 references

T Fehm

8

0 references

M Eichelbaum

9

0 references

M Schwab

10

0 references

language of work or name

0 references

publication date

30 March 2011

0 references

Clinical Pharmacology & Therapeutics

0 references

89

0 references

5

0 references

708-717

0 references

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

TGFbeta2 and TbetaRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Tamoxifen metabolite isomer separation and quantification by liquid chromatography-tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Tamoxifen, soy, and lifestyle factors in Asian American women with breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Pharmacogenomics of tamoxifen therapy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

CYP2D6 and tamoxifen: DNA matters in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Drugs as CYP3A probes, inducers, and inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Coprescription of tamoxifen and medications that inhibit CYP2D6.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Aromatase inhibitors alone or in sequence with tamoxifen - clinical evaluation of the BIG 1-98 trial

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

New Highly Stereoselective Synthesis of (Z)-4-Hydroxytamoxifen and (Z)-4-Hydroxytoremifene via McMurry Reaction

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Rapid and Simple Method to Determine Tamoxifen and Its Major Metabolites in Human Liver Microsomes by High Performance Liquid Chromatography with Fluorescence Detection

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

7 January 2021

based on heuristic

inferred from DOI database lookup

Direct determination of tamoxifen and its four major metabolites in plasma using coupled column high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

7 January 2021

based on heuristic

inferred from DOI database lookup

Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

7 January 2021

based on heuristic

inferred from DOI database lookup

Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/CLPT.2011.27

0 references

Dimensions Publication ID

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57072034&oldid=2213285722"